ADMA BIOLOGICS, INC. 8-K

What Happened

• ADMA Biologics, Inc. announced the results of its 2026 Annual Meeting of Stockholders held June 2, 2026. At the meeting two Class I directors were elected to terms ending at the 2029 Annual Meeting, KPMG LLP was ratified as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and the company’s executive compensation ("Say‑on‑Pay") was approved on a non‑binding, advisory basis. The record date was April 8, 2026.

Key Details

• Shares outstanding (record date): 232,324,283; shares represented at the meeting (quorum): 199,267,547 (≈85.8% voting power).
• Director elections (votes cast excluding broker non‑votes — 176,226,672 total):
  • Alison C. Finger: For 156,849,830; Withheld 19,376,842 (For ≈89.01%).
  • Eduardo Rene Salas: For 171,947,523; Withheld 4,279,149 (For ≈97.57%).
• Ratification of KPMG LLP as auditor: For 198,655,040; Against 329,056; Abstain 283,451 (For ≈99.69% of votes cast).
• Say‑on‑Pay (non‑binding advisory vote): For 168,169,866; Against 7,730,690; Abstain 326,116; Broker non‑votes 23,040,875 (For ≈95.43% of votes cast).

Why It Matters

• Board composition and re‑election of directors affect corporate oversight and strategy execution; both nominees were elected with strong majorities. Ratification of KPMG ensures continuity of the company’s independent audit for FY 2026. The strong advisory approval of executive compensation indicates shareholder support for ADMA’s pay practices, though the vote is non‑binding and does not itself change compensation arrangements.